Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics.
anticholinergic drugs
antipsychotic monotherapy
antipsychotic polypharmacy
first-generation antipsychotics
schizophrenia
second-generation antipsychotic (SGA)
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
11
2021
accepted:
04
04
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
epublish
Résumé
In several clinical guidelines for schizophrenia, long-term use of anticholinergic drugs is not recommended. We investigated the characteristics of the use of anticholinergics in patients with schizophrenia by considering psychotropic prescription patterns and differences among hospitals. A cross-sectional, retrospective prescription survey at the time of discharge was conducted on 2027 patients with schizophrenia from 69 Japanese hospitals. We examined the relations among psychotropic drug prescriptions regarding anticholinergic prescription. We divided the hospitals into three groups-low rate group (LG), medium rate group (MG), and high rate group (HG)-according to their anticholinergic prescription rates, and analyzed the relationship between anticholinergic prescription rates and antipsychotic prescription. Anticholinergic drugs were prescribed to 618 patients (30.5%), and the prescription rates were significantly higher for high antipsychotic doses, antipsychotic polypharmacy, and first-generation antipsychotics (FGAs) use. The anticholinergic prescription rate varied considerably among hospitals, ranging from 0 to 66.7%, and it was significantly higher in patients with antipsychotic monotherapy, antipsychotic polypharmacy, and normal and high doses of antipsychotics in HG than in those LG and MG. The anticholinergics prescription rate in patients with second-generation antipsychotic monotherapy in HG was also significantly higher than in those LG and MG; however, the difference was no longer significant in patients with FGA monotherapy. Conclusively, in addition to high antipsychotic doses, antipsychotic polypharmacy, and FGA use, hospital characteristics influence the prescribing of anticholinergic drugs.
Identifiants
pubmed: 35656353
doi: 10.3389/fpsyt.2022.823826
pmc: PMC9152135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
823826Informations de copyright
Copyright © 2022 Hori, Yasui-Furukori, Hasegawa, Iga, Ochi, Ichihashi, Furihata, Kyo, Takaesu, Tsuboi, Kodaka, Onitsuka, Okada, Murata, Kashiwagi, Iida, Hashimoto, Ohi, Yamada, Ogasawara, Yasuda, Muraoka, Usami, Numata, Takeshima, Yamagata, Nagasawa, Tagata, Makinodan, Kido, Katsumoto, Komatsu, Matsumoto, Kubota, Miura, Hishimoto, Watanabe, Inada, Kawasaki and Hashimoto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sleep Med. 2022 Jan;89:23-30
pubmed: 34875519
Hum Psychopharmacol. 2012 Jan;27(1):70-5
pubmed: 22249957
Can J Psychiatry. 1994 Mar;39(2):74-84
pubmed: 7908605
Neuropsychopharmacol Rep. 2022 Jun;42(2):221-225
pubmed: 35272393
BMC Med. 2018 May 21;16(1):76
pubmed: 29783964
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
J Clin Psychiatry. 2007 Aug;68(8):1218-25
pubmed: 17854246
Psychiatry Clin Neurosci. 2019 Aug;73(8):476-485
pubmed: 31077519
Pharm World Sci. 2007 Jun;29(3):126-30
pubmed: 17333501
World J Biol Psychiatry. 2012 Jul;13(5):318-78
pubmed: 22834451
Schizophr Res. 2006 Sep;86(1-3):138-46
pubmed: 16793238
Lancet. 2012 Dec 15;380(9859):2129-43
pubmed: 23245605
Pharmacopsychiatry. 2011 May;44(3):114-8
pubmed: 21491361
Psychiatry Clin Neurosci. 2020 Feb;74(2):149-155
pubmed: 31707749
Am J Psychiatry. 2004 Jan;161(1):116-24
pubmed: 14702259
Curr Opin Psychiatry. 2007 May;20(3):268-72
pubmed: 17415081
Australas Psychiatry. 2017 Dec;25(6):600-602
pubmed: 28875719
Br J Clin Pharmacol. 2009 Aug;68(2):238-42
pubmed: 19694744
Psychiatry Clin Neurosci. 2019 Oct;73(10):642-648
pubmed: 31437336
J Psychopharmacol. 2020 Jan;34(1):3-78
pubmed: 31829775
Acta Psychiatr Scand Suppl. 1987;334:1-100
pubmed: 2887090
Asian J Psychiatr. 2019 Oct;45:74-80
pubmed: 31520884
Acta Psychiatr Scand. 2006 Feb;113(2):135-41
pubmed: 16423165
Psychiatry Clin Neurosci. 2014 Jan;68(1):37-49
pubmed: 24102938
Arch Gen Psychiatry. 1992 Jul;49(7):538-44
pubmed: 1352677
Neuropsychopharmacol Rep. 2022 Mar;42(1):3-9
pubmed: 34854260
Neuropsychopharmacol Rep. 2021 Jun;41(2):199-206
pubmed: 33704931
Psychiatry Clin Neurosci. 2020 May;74(5):289-293
pubmed: 31994282
Psychiatry Clin Neurosci. 2019 Jul;73(7):394-399
pubmed: 30968478
Biomed Res Int. 2014;2014:656370
pubmed: 24995318
J Psychiatr Res. 2013 Dec;47(12):1843-8
pubmed: 24054464
Br J Psychiatry. 2011 Oct;199(4):266-8
pubmed: 22187726
Psychiatry Clin Neurosci. 2022 Jan;76(1):1-14
pubmed: 34716732
Psychiatry Res. 2017 Sep;255:198-203
pubmed: 28578178
J Psychopharmacol. 2012 Sep;26(9):1167-74
pubmed: 22651987
Asian J Psychiatr. 2021 Sep;63:102744
pubmed: 34325252
Psychiatry Clin Neurosci. 2020 Dec;74(12):667-669
pubmed: 32881226
Neuropsychiatr Dis Treat. 2013;9:1381-92
pubmed: 24092977
Psychiatry Res. 2007 Aug 30;152(2-3):165-72
pubmed: 17445906
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Neuropsychiatr Dis Treat. 2014 Mar 26;10:527-33
pubmed: 24707178
Neuropsychopharmacol Rep. 2020 Sep;40(3):281-286
pubmed: 32602667
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):78-83
pubmed: 20828595
Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7
pubmed: 25601291
J Clin Psychopharmacol. 2011 Aug;31(4):497-502
pubmed: 21694629
Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):183-192
pubmed: 31908124
Int J Neuropsychopharmacol. 2005 Sep;8(3):427-38
pubmed: 15804371